A Phase II/III Randomized Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-5172 and MK-8742 in Subjects with Chronic Hepatitis C Virus Infection and Chronic Kidney Disease

Serum Lipopolysaccharide (LPS) Measurement to Predict Progression of Fibrosis in Liver Transplant Recipients with Hepatitis C Virus.

A Multicenter, Double-Blind, Sponsor-Open Trial of IDN- 6556 in Subjects Who had Hepatitis C Virus (HCV) Reinfection and Liver Fibrosis following Orthotopic Liver Transplantation for Chronic HCV Infection and Who Subsequently Achieved a Sustained Virologic Response Following anti-HCV Therapy

In addition to a multidisciplinary approach to weight loss and risk factor modification, targeted treatment specific for each individual patient remains our goal. We collaborate at every level — from genetics to experimental therapeutics/clinical trials to behavior modification — to offer you a comprehensive plan for the management of fatty liver disease.

We also work in close partnership with the Institute of Genomic Medicine as an area of focus within the Precision Medicine Initiative. 

Over the last 20 years liver transplantation has become the standard of care and the only cure for end stage liver disease. Its success has led to over 4,500 transplants performed yearly. But there are at least 18,000 patients on the transplantation list awaiting cadaveric liver donation. As the waiting list has expanded, waiting time has also grown. As a result, patient mortality has increased while awaiting transplantation and patients are often critically ill by the time of transplantation.